Changes Of Expression Of FOXP3 And IL-27 MRNA During Specific Immunotherapy For Children With Allergic Asthma

Background and ObjectiveThe allergic asthma is one kind of chronic respiratory passage diseases. The incidence rate of this disease is high in the children of our country and still increasing. The SIT (specific immunotherapy) can change the course of disease. It may be the only etiotropic treatment. Then we remain unkown its mechanism exactly. So this study was designed to survey the changes of expression of FOXP3 transcription factor, IL-27 p28 and EBI3 mRNA in peripheral blood mononuclear cells (PBMCs) which were from patients with allergic asthma that treated with house dust mites specific immunotherapy.MethodsThe blood of thirty-nine patients with allergic asthma was collected depended on their therapy time from the department of pediatics of first affiliated hospital of Zhengzhou Univercity from November,2007 to September,2009. PBMCs were extracted from the peripheral venous blood which collected at the pre-SIT, post-SIT for 1 year or post-SIT for 2 years time. Then extracted total RNA and reverse transcription was proceded. The expression levels of FOXP3,IL-27 p28 and EBI3 mRNA were detected by SYBR Green I Real-Time RT-PCR. Meanwhile, the curative effects were detected.Results With the progression of SIT, the symptom of allergic asthma was obviously ameliorated. The expression levels of FOXP3 and IL-27 p28 mRNA were obviously increased at one year after SIT, and were 6.02-fold and 2.18-fold comparing to that before therapy respectively. Two years after SIT, the expression of FOXP3 mRNA decreased to 2.22-fold of that before therapy and the expression of IL-27p28 mRNA decreased to 1.05-fold the level of before therapy. The change of IL-27 EBI3 mRNA expression was not significant during the therapy.ConclusionsThe SIT is efficient for the patients with allergic asthma; the transcription factor FOXP3 and IL-27 may play important role in pathogenesis of the SIT.